Veradermics' Oral Minoxidil Shows Promising Results in Female Pattern Hair Loss Trial — Veradermics, Incorporated

Event summary

Veradermics' Phase 2 trial (Study '207') of oral VDPHL01 in female pattern hair loss showed positive topline results, with average hair count increases of 22.7–23.3 hairs/cm² and high patient-reported improvement rates.
The study demonstrated rapid onset of activity, consistent response across participants, and no treatment-related serious adverse events or cardiac-origin AESIs.
Veradermics plans to host a conference call on July 15, 2026, to discuss the results, with topline data from the Phase 2/3 Study '306' anticipated in 1H 2027.

The big picture

Veradermics' positive Phase 2 results for VDPHL01 come at a time when the pattern hair loss market has seen no new FDA-approved prescription medicines in nearly 30 years. The company is positioning itself to address a significant unmet need, with the potential to transform treatment options for both female and male pattern hair loss. The upcoming Phase 2/3 readout in 1H 2027 will be critical in determining the commercial viability of VDPHL01.

What we're watching

Regulatory Pathway: Whether the positive Phase 2 results will translate into successful Phase 2/3 outcomes and ultimately FDA approval for VDPHL01 as the first oral treatment for female pattern hair loss.
Market Potential: The pace at which Veradermics can capture the estimated $30 billion aesthetics market, targeting 30 million women with female pattern hair loss.
Competitive Dynamics: How Veradermics' extended-release formulation of minoxidil will differentiate itself from existing topical and nutraceutical options in the pattern hair loss treatment landscape.